Jenburkt Pharmaceuticals Limited Revenue and Competitors
Estimated Revenue & Valuation
- Jenburkt Pharmaceuticals Limited's estimated annual revenue is currently $37.9M per year.
- Jenburkt Pharmaceuticals Limited's estimated revenue per employee is $140,000
Employee Data
- Jenburkt Pharmaceuticals Limited has 271 Employees.
- Jenburkt Pharmaceuticals Limited grew their employee count by 36% last year.
Jenburkt Pharmaceuticals Limited's People
Name | Title | Email/Phone |
---|
What Is Jenburkt Pharmaceuticals Limited?
Our purpose at Jenburkt Pharmaceuticals Ltd is to serve those in need of quality healthcare by bringing revolutionary, life-changing therapeutic solutions that are accessible to all. We believe in serving our patients – through them, we serve God, humanity and nation. Way back in the twentieth century, a visionary in the field of healthcare and philanthropic work – Shri Nandlal Mulji Bhuta laid the foundation for several companies. Today, with over 850+ committed team members across functions pan-India,we have 11 million+ prescriptions generated annually from 400,000+ pharmacies across the globe. Our organisation caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. We enjoy an international presence, with our products exported to 13 countries globally including niche segments. In an ever-changing health landscape, our rapt attention to market trends, innovation, our keen focus on quality above all else, and our team's restless perseverance to deliver ground-breaking new healthcare solutions set us apart.
keywords:N/AN/A
Total Funding
271
Number of Employees
$37.9M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Jenburkt Pharmaceuticals Limited News
About Jenburkt Pharmaceuticals Ltd. Founded in 1985, Jenburkt Pharmaceuticals Ltd. is a public-listed pharmaceutical organisation headquartered...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $72.4M | 271 | 3% | N/A |
#2 | $43.2M | 271 | 14% | N/A |
#3 | $62.6M | 271 | 33% | N/A |
#4 | $62.6M | 271 | 30% | N/A |
#5 | $42.2M | 272 | 18% | N/A |